Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 127
Filter
Add more filters

Complementary Medicines
Publication year range
1.
J Am Heart Assoc ; 12(1): e028050, 2023 01 03.
Article in English | MEDLINE | ID: mdl-36583425

ABSTRACT

Background Anti-cancer vascular endothelial growth factor inhibitors (VEGFI) frequently induce a rise in blood pressure (BP). The most effective treatment of this BP rise is currently unknown, and risk factors and its association with survival remain inconclusive. Methods and Results Baseline characteristics and BP readings were retrospectively collected from oncology patients who received oral VEGFI treatment (sorafenib, sunitinib, pazopanib, regorafenib, lenvatinib, or cabozantinib). Risk factors for a clinically relevant BP rise (increase of ≥20 mm Hg in systolic BP or ≥10 mm Hg in diastolic BP) were investigated via logistic regression (relative), efficacy of antihypertensives via unpaired t-tests, and association of BP rise with survival via Cox regression analysis. In total, 162 (47%) of 343 included patients developed a clinically relevant BP rise ≥7 days after VEGFI treatment initiation. Both calcium channel blockers and renin-angiotensin system inhibitors effectively reduced systolic BP (-24.1 and -18.2 mm Hg, respectively) and diastolic BP (-12.0 and -11.0 mm Hg, respectively). Pazopanib therapy (odds ratio, 2.71 [95% CI, 1.35-5.42; P=0.005], compared with sorafenib) and estimated glomerular filtration rate <60 mL/min per 1.73 m2 (OR, 1.75 [95% CI, 0.99-3.18, P=0.054]) were risk factors for a BP rise, whereas a baseline BP ≥140/90 mm Hg associated with a lower risk (OR, 0.39 [95% CI, 0.25-0.62, P<0.001]). Only for renal cell carcinoma, BP rise was associated with a substantially improved median overall survival compared with no BP rise: 45.4 versus 20.3 months, respectively, P=0.003. Conclusions The type of VEGFI, baseline BP, and baseline estimated glomerular filtration rate determine the VEGFI-induced BP rise. Both calcium channel blockers and renin-angiotensin system inhibitors are effective antihypertensive treatments. Particularly in patients with renal cell carcinoma, a BP rise is associated with improved overall survival.


Subject(s)
Carcinoma, Renal Cell , Hypertension , Kidney Neoplasms , Humans , Blood Pressure , Hypertension/chemically induced , Hypertension/drug therapy , Hypertension/metabolism , Vascular Endothelial Growth Factor A/pharmacology , Calcium Channel Blockers/therapeutic use , Carcinoma, Renal Cell/drug therapy , Carcinoma, Renal Cell/chemically induced , Cohort Studies , Sorafenib/adverse effects , Retrospective Studies , Antihypertensive Agents/adverse effects , Angiogenesis Inhibitors/adverse effects , Kidney Neoplasms/chemically induced , Kidney Neoplasms/drug therapy
2.
World J Urol ; 41(4): 899-907, 2023 Apr.
Article in English | MEDLINE | ID: mdl-35867141

ABSTRACT

PURPOSE: The high incidence of upper urinary tract urothelial carcinoma (UTUC) in Taiwan is largely due to exposure to aristolochic acid (AA), a principal component of Aristolochia-based herbal medicines. Here we systematically review the molecular epidemiology, clinical presentation and biomarkers associated with AA-induced UTUC. METHODS: This is a narrative review. Medline, Embase, and Web of Science were searched from inception to December 31, 2021. Studies evaluating the association, detection, and clinical characteristics of AA and UTUC were included. RESULTS: A nationwide database revealed 39% of the Taiwanese population had been exposed to AA-containing herbs between 1997 and 2003. Epidemiological reports revealed AA posed a significantly higher hazard for renal failure and UTUC in herbalists and the general population who ingested AA-containing herbs. The presence of aristolactam-DNA adducts and a distinctive signature mutation, A:T to T:A transversions, located predominantly on the non-transcribed DNA strand, with a strong preference for deoxyadenosine in a consensus sequence (CAG), was observed in many UTUC patients. Clinically, AA-related UTUC patients were characterized by a younger age, female gender, impaired renal function and recurrence of contralateral UTUC. To date, there are no preventive measures, except prophylactic nephrectomy, for subjects at risk of AA nephropathy or AA-related UTUC. CONCLUSION: AA exposure via Aristolochia-based herbal medicines is a problem throughout Taiwan, resulting in a high incidence of UTUC. Aristolactam-DNA adducts and a distinctive signature mutation, A:T to T:A transversions, can be used as biomarkers to identify AA-related UTUC. AA-related UTUC is associated with a high recurrence rate of contralateral UTUC.


Subject(s)
Aristolochic Acids , Carcinoma, Transitional Cell , Drugs, Chinese Herbal , Kidney Neoplasms , Ureteral Neoplasms , Urinary Bladder Neoplasms , Urinary Tract , Humans , Female , Carcinoma, Transitional Cell/chemically induced , Carcinoma, Transitional Cell/epidemiology , Carcinoma, Transitional Cell/genetics , DNA Adducts/adverse effects , Drugs, Chinese Herbal/adverse effects , Taiwan/epidemiology , Carcinogens , Kidney Neoplasms/chemically induced , Kidney Neoplasms/epidemiology , Kidney Neoplasms/genetics , Aristolochic Acids/adverse effects , Aristolochic Acids/analysis , Ureteral Neoplasms/chemically induced , Ureteral Neoplasms/epidemiology
3.
J Oleo Sci ; 71(10): 1481-1492, 2022 Sep 30.
Article in English | MEDLINE | ID: mdl-36089399

ABSTRACT

Renal tissue plays a crucial function in maintaining homeostasis, making it vulnerable to xenobiotic toxicity. Pueraria montana has more beneficial potential against the various diseases and has long history used as a traditional Chinese medicine. But its effect against the renal cancer not scrutinize. The goal of this study is to see if Pueraria montana can protect rats from developing kidney tumors caused by diethylnitrosamine (DEN) and ferric nitrite (Fe-NTA). Wistar rats was selected for the current study and DEN (use as an inducer) and Fe-NTA (promoter) for induction the renal cancer. For 22 weeks, the rats were given orally Pueraria montana (12.5, 25, and 50 mg/kg) treatment. At regular intervals, the body weight and food intake were calculated. The rats were macroscopically evaluated for identification of cancer in the renal tissue. The renal tumor makers, renal parameters, antioxidant enzymes, phase I and II enzymes, inflammatory cytokines and mediators were estimated at end of the experimental study. Pueraria montana treated rats displayed the suppression of renal tumors, incidence of the tumors along with suppression of tumor percentage. Pueraria montana treated rats significantly (p < 0.001) increased body weight and suppressed the renal weight and food intake. It also reduced the level of renal tumor marker ornithine decarboxylase (ODC) and [3H] thymidine incorporation along with suppression of renal parameter such as uric acid, blood urea nitrogen (BUN), urea and creatinine. Pueraria montana treatment significantly (p < 0.001) altered the level of phase enzymes and antioxidant. Pueraria montana treatment significantly (p < 0.001) repressed the level of tumor necrosis factor-α (TNF-α), interleukin-1ß (IL-1ß), interleukin-6 (IL-6) and improved the level of interleukin-10 (IL-10). Pueraria montana treatment suppressed the level of prostaglandin (PGE2), cyclooxygenase-2 (COX-2), nuclear kappa B factor (NF-κB) and transforming growth factor beta 1 (TGF-ß1). Pueraria montana suppressed the inflammatory necrosis, size the bowman capsules in the renal histopathology. Pueraria montana exhibited the chemoprotective effect via dual mechanism such as suppression of inflammatory reaction and oxidative stress.


Subject(s)
Kidney Neoplasms , Pueraria , Animals , Antioxidants/pharmacology , Biomarkers, Tumor/metabolism , Biomarkers, Tumor/pharmacology , Body Weight , Creatinine/pharmacology , Cyclooxygenase 2/metabolism , Diethylnitrosamine/pharmacology , Ferric Compounds , Inflammation/drug therapy , Interleukin-10 , Interleukin-1beta/metabolism , Interleukin-6/metabolism , Kidney Neoplasms/chemically induced , Kidney Neoplasms/drug therapy , Kidney Neoplasms/metabolism , NF-kappa B/metabolism , Nitrilotriacetic Acid/analogs & derivatives , Nitrites/pharmacology , Ornithine Decarboxylase/metabolism , Ornithine Decarboxylase/pharmacology , Oxidative Stress , Prostaglandins , Prostaglandins E/metabolism , Prostaglandins E/pharmacology , Pueraria/metabolism , Rats , Rats, Wistar , Thymidine/metabolism , Thymidine/pharmacology , Transforming Growth Factor beta1/metabolism , Transforming Growth Factor beta1/pharmacology , Tumor Necrosis Factor-alpha/metabolism , Urea , Uric Acid/pharmacology , Xenobiotics/pharmacology
4.
Int J Cancer ; 150(7): 1134-1140, 2022 04 01.
Article in English | MEDLINE | ID: mdl-34910310

ABSTRACT

Evidence on the association between selenium and cancer risk is inconclusive. We conducted a Mendelian randomization study to examine the associations of selenium levels with 22 site-specific cancers and any cancer. Single nucleotide polymorphisms (SNPs) strongly associated with toenail and blood (TAB) and blood selenium levels in mild linkage disequilibrium (r2 < .3) were used as instrumental variables. Genetic associations of selenium-associated SNPs with cancer were obtained from the UK Biobank including a total of 59 647 cancer cases and 307 914 controls. Associations with P < .1 in UK Biobank were tested for replication in the FinnGen consortium comprising more than 180 000 individuals. The inverse-variance weighted method accounting for linkage disequilibrium was used to estimate the associations. Genetically predicted TAB selenium levels were not associated with the risk of the 22 site-specific cancers or any cancer (all 22 site-specific cancers). Similarly, we observed no strong association for genetically predicted blood selenium levels. However, genetically predicted blood selenium levels showed suggestive associations with risk of kidney cancer (odds ratio [OR] per one-unit increase in log-transformed levels: 0.83; 95% confidence interval [CI]: 0.67-1.03) and multiple myeloma (OR: 1.40; 95% CI: 1.02-1.93). The same direction of association for kidney cancer but not for multiple myeloma was observed in FinnGen. In the metaanalysis of UK Biobank and FinnGen, the OR of kidney cancer was 0.83 (95% CI: 0.69-1.00). Our study suggests that high selenium status may not prevent cancer development. The associations for kidney cancer and multiple myeloma need to be verified in well-powered studies.


Subject(s)
Kidney Neoplasms/chemically induced , Mendelian Randomization Analysis/methods , Multiple Myeloma/chemically induced , Selenium/adverse effects , Humans , Nails/chemistry , Polymorphism, Single Nucleotide , Selenium/analysis , Selenium/blood
5.
Oxid Med Cell Longev ; 2021: 7665169, 2021.
Article in English | MEDLINE | ID: mdl-34630852

ABSTRACT

The present work was designed to assess the efficacy of Silybum marianum total extract (STE), silymarin (Sm), and silibinin (Sb) against experimentally induced renal carcinogenesis in male Wistar rats and their roles in regulating oxidative stress, inflammation, apoptosis, and carcinogenesis. The diethylnitrosamine (DEN)/2-acetylaminofluorene (AAF)/carbon tetrachloride (CCl4)-administered rats were orally treated with STE (200 mg/kg b.w.), Sm (150 mg/kg b.w.), and Sb (5 mg/kg b.w.) every other day either from the 1st week or from the 16th week of carcinogen administration to the end of 25th week. The treatments with STE, Sm, and Sb attenuated markers of toxicity in serum, decreased kidney lipid peroxidation (LPO), and significantly reinforced the renal antioxidant armory. The biochemical results were further confirmed by the histopathological alterations. The treatments also led to suppression of proinflammatory mediators such as NF-κß, p65, Iκßα, and IL-6 in association with inhibition of the PI3K/Akt pathway. Furthermore, they activated the expressions of PPARs, Nrf2, and IL-4 in addition to downregulation of apoptotic proteins p53 and caspase-3 and upregulation of antiapoptotic mediator Bcl-2. The obtained data supply potent proof for the efficacy of STE, Sm, and Sb to counteract renal carcinogenesis via alteration of varied molecular pathways.


Subject(s)
Antineoplastic Agents, Phytogenic/administration & dosage , Apoptosis/drug effects , Carcinogenesis/drug effects , Carcinogenesis/metabolism , Kidney Neoplasms/drug therapy , Kidney Neoplasms/metabolism , NF-E2-Related Factor 2/metabolism , NF-kappa B/metabolism , Oxidative Stress/drug effects , PPAR gamma/metabolism , Phosphatidylinositol 3-Kinases/metabolism , Phytotherapy/methods , Plant Extracts/administration & dosage , Proto-Oncogene Proteins c-akt/metabolism , Signal Transduction/drug effects , Silybin/administration & dosage , Silybum marianum/chemistry , Silymarin/administration & dosage , Animals , Carcinogenesis/chemically induced , Disease Models, Animal , Kidney Neoplasms/chemically induced , Kidney Neoplasms/prevention & control , Male , Rats , Rats, Wistar
6.
Biomed Pharmacother ; 139: 111636, 2021 Jul.
Article in English | MEDLINE | ID: mdl-33957566

ABSTRACT

This study was designed to reveal the protective effects of dietary supplementation of curcumin against renal cell tumours and oxidative stress induced by renal carcinogen iron nitrilotriacetate (Fe-NTA) in ddY male mice. The results showed that mice treated with a renal carcinogen, Fe-NTA, a 35% renal cell tumour incidence was noticed, whereas renal cell tumour occurrence was elevated to 80% in Fe-NTA promoted and N-diethylnitrosamine (DEN)-initiated mice as compared with saline- treated mice. No incidence of tumours has been observed in DEN-initiated non-promoted mice. Diet complemented with 0.5% and 1.0% curcumin fed prior to, during and after treatment with Fe-NTA in DEN-initiated animals, tumour incidence was reduced dose-dependently to about 45% and 30% respectively. Immunohistochemical studies also revealed the increased formation of 4-hydroxy-2-nonenal (HNE)-modified protein adducts and 8-hydroxy-2'-deoxyguanosine (8-OHdG) in kidney tissue of mice treated with an intraperitoneal injection of Fe-NTA (6.0 mg Fe/kg body weight.). Furthermore, Fe-NTA treatment of mice also resulted in significant elevation of malondialdehyde (MDA), serum urea, and creatinine and decreases renal glutathione. However, the changes in most of these parameters were attenuated dose-dependently by prophylactic treatment of animals with 0.5% and 1% curcumin diet, this may be due to its antioxidative impact of curcumin. These results suggest that intake of curcumin is beneficial for the prevention of renal cell tumours and oxidative stress damage mediated by renal carcinogen, Fe-NTA.


Subject(s)
Antineoplastic Agents, Phytogenic/therapeutic use , Antioxidants/therapeutic use , Carcinoma, Renal Cell/chemically induced , Carcinoma, Renal Cell/drug therapy , Curcumin/therapeutic use , Kidney Neoplasms/chemically induced , Kidney Neoplasms/drug therapy , Oxidative Stress/drug effects , 8-Hydroxy-2'-Deoxyguanosine , Aldehydes , Animals , Anticarcinogenic Agents/pharmacology , Blood Urea Nitrogen , Carcinogens , Creatinine/blood , Diet , Diethylnitrosamine , Dose-Response Relationship, Drug , Ferric Compounds , Male , Mice , Nitrilotriacetic Acid/analogs & derivatives
7.
Curr Drug Deliv ; 18(5): 634-644, 2021.
Article in English | MEDLINE | ID: mdl-32914714

ABSTRACT

OBJECTIVE: Madhuca longifolia has been used for the treatment of renal cancer. Therefore, the current study describes the protective effects of biofabricated silver nanoparticles (MLAg- NPs) using Madhuca longifolia aqueous leaves extract against diethylnitrosamine (DEN) induced Renal Cell Carcinoma (RCC) in rats. METHODS: Animals were categorized into five groups and treated with doses of silver nanoparticles for 16 weeks. Antineoplastic effect in renal cancer was dose dependent to control the macroscopical variations when compared to DEN induced group. Significant changes were observed in biochemical parameters and dose graded improvement in the level of antioxidants parameters were accountable for its protective nature. RESULTS: Silver nanoparticles in dose dependent manner was effective to modify the raised levels of pro-inflammatory cytokines and inflammatory mediators during renal cancer. Alteration in renal histopathology were also detected in the silver nanoparticles treated group, which show its safety concern. Biofabricated silver nanoparticles (MLAgNPs) using Madhuca longifolia can convey significant chemo-protective effect against renal cancer by suppressing the IL-6, TNF-α and IL-1ß by nuclear factor-kappa B (NF-κB) pathway. CONCLUSION: Our outcomes implicates that biofabricated MLAgNPs exhibited a chemoprotective potential in the prevention and intervention of RCC.


Subject(s)
Kidney Neoplasms , Madhuca , Metal Nanoparticles , Animals , Diethylnitrosamine/toxicity , Kidney Neoplasms/chemically induced , Kidney Neoplasms/drug therapy , Oxidative Stress , Plant Extracts/pharmacology , Rats , Rats, Wistar , Silver
8.
Sci Rep ; 9(1): 19860, 2019 12 27.
Article in English | MEDLINE | ID: mdl-31882686

ABSTRACT

Cancer is a public health problem worldwide. Taiwan has a higher incidence rate of urological cancers than many Asian countries do. Aristolochic acid has been considered a potent carcinogen. In this study, we examined whether the cessation of the sales and preparation of aristolochic acid-containing Chinese herbal products (AA-CHPs) in Taiwan contributed to a decline in the incidence rates of bladder cancer, carcinomas of the renal pelvis and other urinary organs, and kidney cancer. We conducted an interrupted time-series analysis of long-term trends in the incidence rates of the aforementioned cancers between 1995 and 2013 in Taiwan. The incidence rates of bladder cancer and carcinomas of the renal pelvis and other urinary organs decreased considerably after 2008 and 2011, respectively. Notably, these change-of-slope time points occurred after the year 2003, when a ban on AA-CHPs was imposed in Taiwan. The ban on AA-CHPs in Taiwan was possibly associated with the reduction in the incidence of bladder cancer and carcinomas of the renal pelvis and other urinary organs.


Subject(s)
Aristolochic Acids/toxicity , Carcinogens/toxicity , Drugs, Chinese Herbal/toxicity , Urologic Neoplasms/epidemiology , Urologic Neoplasms/mortality , Humans , Incidence , Kidney Neoplasms/chemically induced , Kidney Neoplasms/epidemiology , Kidney Neoplasms/mortality , Kidney Pelvis/drug effects , Kidney Pelvis/pathology , Models, Statistical , Taiwan/epidemiology , Urologic Neoplasms/chemically induced
9.
Semin Nephrol ; 39(3): 284-296, 2019 05.
Article in English | MEDLINE | ID: mdl-31054628

ABSTRACT

Balkan endemic nephropathy is a chronic tubulointerstitial disease with insidious onset, slowly progressing to end-stage renal disease and frequently associated with urothelial carcinoma of the upper urinary tract (UTUC). It was described in South-East Europe at the Balkan peninsula in rural areas around tributaries of the Danube River. After decades of intensive investigation, the causative factor was identified as the environmental phytotoxin aristolochic acid (AA) contained in Aristolochia clematitis, a common plant growing in wheat fields that was ingested through home-baked bread. AA initially was involved in the outbreak of cases of rapidly progressive renal fibrosis reported in Belgium after intake of root extracts of Aristolochia fangchi imported from China. A high prevalence of UTUC was found in these patients. The common molecular link between Balkan and Belgian nephropathy cases was the detection of aristolactam-DNA adducts in renal tissue and UTUC. These adducts are not only biomarkers of prior exposure to AA, but they also trigger urothelial malignancy by inducing specific mutations (A:T to T:A transversion) in critical genes of carcinogenesis, including the tumor-suppressor TP53. Such mutational signatures are found in other cases worldwide, particularly in Taiwan, highlighting the general public health issue of AA exposure by traditional phytotherapies.


Subject(s)
Aristolochic Acids/toxicity , Balkan Nephropathy/chemically induced , Carcinoma, Transitional Cell/chemically induced , Environmental Exposure/adverse effects , Kidney Neoplasms/chemically induced , Ureteral Neoplasms/chemically induced , Animals , Aristolochia , Balkan Nephropathy/diagnosis , Balkan Nephropathy/pathology , Balkan Nephropathy/therapy , Carcinogens/toxicity , DNA Adducts , Humans , Mass Screening
10.
Environ Toxicol ; 33(10): 1069-1077, 2018 Oct.
Article in English | MEDLINE | ID: mdl-30098279

ABSTRACT

The present study was designed to evaluate the protective effects of hesperidin, a flavonoid on DEN initiated and Fe-NTA promoted renal carcinogenesis in Wistar rats. Renal cancer was initiated by a single i.p. injection of DEN (200 mg/kg b.wt.) and promoted with Fe-NTA (9 mg Fe/kg b.wt. i.p.) twice a week for 16 weeks. Rats were simultaneously administered with hesperidin (100 and 200 mg/kg b.wt.) for 16 consecutive weeks. The chemopreventive effect of hesperidin was assessed in terms of antioxidant activities, renal function, PGE2 level, and the expressions of COX-2 and VEGF. Hesperidin decreased the DEN and Fe-NTA induced lipid peroxidation, improved the renal function (by decreasing the levels of BUN, creatinine, and KIM-1) and restored the renal antioxidant armory (GSH, GPx, GR, SOD, and catalase). Hesperidin was also found to decrease the level of PGE2 and downregulate the expressions of COX-2 and VEGF. Histological findings further revealed the protective effects of hesperidin against DEN and Fe-NTA induced kidney damage. The result of our present findings suggest that hesperidin may be a promising modulator in preventing renal cancer possibly by virtue of its ability to alleviate oxidative stress and inhibit COX-2/PGE2 pathway.


Subject(s)
Anticarcinogenic Agents/therapeutic use , Carcinoma, Renal Cell/drug therapy , Cyclooxygenase 2/metabolism , Dinoprostone/metabolism , Hesperidin/therapeutic use , Kidney Neoplasms/drug therapy , Animals , Anticarcinogenic Agents/pharmacology , Antioxidants/metabolism , Carcinogenesis/chemically induced , Carcinogenesis/drug effects , Carcinoma, Renal Cell/chemically induced , Carcinoma, Renal Cell/metabolism , Cell Proliferation/drug effects , Diethylnitrosamine , Ferric Compounds , Hesperidin/pharmacology , Kidney/metabolism , Kidney Neoplasms/chemically induced , Kidney Neoplasms/metabolism , Lipid Peroxidation , Male , Nitrilotriacetic Acid/analogs & derivatives , Oxidative Stress , Plant Extracts/pharmacology , Rats, Wistar
11.
Intern Med J ; 47(12): 1422-1432, 2017 Dec.
Article in English | MEDLINE | ID: mdl-28892303

ABSTRACT

BACKGROUND/OBJECTIVES: The risk of renal cell carcinoma (RCC) in individuals who regularly drink coffee is controversial. Several antioxidant compounds in coffee have been proposed to reduce the risk of RCC, while the findings from several studies raise concerns regarding a potential increased risk of RCC with coffee consumption. AIM: This meta-analysis aims to evaluate the association between coffee consumption and RCC. METHODS: A literature search was performed using MEDLINE, EMBASE and Cochrane Database of Systematic Reviews from inception until December 2016. Studies that reported odd ratios or hazard ratios comparing the risk of RCC in individuals who consumed a significant amount of coffee (at least one cup of coffee per day) versus those who did not consume coffee were included. Pooled risk ratios (RR) and 95% confidence intervals (CI) were computed using a random-effect, generic inverse variance method. RESULTS: Twenty-two observational studies (16 case-control and 6 cohort studies) were included in our analysis to assess the association between RCC and coffee consumption. The pooled RR of RCC in individuals consuming coffee was 0.99 (95% CI, 0.89-1.11). Subgroup analyses stratified by gender showed pooled RRs of RCC of 1.15 (95% CI, 0.85-1.55) in females and 0.87 (95% CI, 0.72-1.04) in males. CONCLUSIONS: Our study demonstrates no significant association between coffee consumption and RCC. Thus, coffee consumption is likely not a risk factor for RCC. Whether coffee consumption has a potential role in reduced risk of RCC, particularly in men, requires further investigations.


Subject(s)
Carcinoma, Renal Cell/diagnosis , Carcinoma, Renal Cell/epidemiology , Coffee , Kidney Neoplasms/diagnosis , Kidney Neoplasms/epidemiology , Carcinoma, Renal Cell/chemically induced , Case-Control Studies , Coffee/adverse effects , Cohort Studies , Female , Humans , Kidney Neoplasms/chemically induced , Male , Observational Studies as Topic/methods , Risk Factors
12.
Inflammopharmacology ; 25(1): 159-175, 2017 Feb.
Article in English | MEDLINE | ID: mdl-28155120

ABSTRACT

A new compound derivative of glycoside 19-α-hydroxy-ursolic acid glucoside (19-α-hydroxyurs-12(13)-ene-28-oic acid-3-O-ß-D-glucopyranoside (HEG) was isolated from whole plant of Wedelia calendulacea (Compositae). The structure was elucidated and established by standard spectroscopy approaches. Diethylnitrosamine (DEN) (200 mg/kg) and ferric nitrilotriacetate (Fe-NTA) (9 mg/kg) were used for induction of renal cell carcinoma (RCC) in the rats. The rats were further divided into different groups and were treated with HEG doses for 22 weeks. Anti-cancer effect in RCC by HEG was dose dependent to restrict the macroscopical changes as compared to DEN + Fe-NTA-control animals. Significant alteration in biochemical parameters and dose-dependent alleviation in Phase I and Phase II antioxidant enzymes were responsible for its chemo-protective nature. HEG in dose-dependent manner was significant to alter the elevated levels of pro-inflammatory cytokines and inflammatory mediators during RCC. The histopathological changes were observed in the HEG pre-treated group, which was proof for its safety concern as far as its toxicity is concerned. The isolated compound HEG can impart momentous chemo-protection against experimental RCC by suppressing the cyclooxygenase (COX-2) and prostaglandin E2 (PGE2) expression via nuclear factor-kappa B (NF-κB) pathway.


Subject(s)
Cyclooxygenase 2/metabolism , Dinoprostone/metabolism , Glycosides/therapeutic use , Kidney Neoplasms/metabolism , NF-kappa B/metabolism , Wedelia , Animals , Diethylnitrosamine/toxicity , Dinoprostone/antagonists & inhibitors , Dose-Response Relationship, Drug , Down-Regulation/drug effects , Down-Regulation/physiology , Glycosides/isolation & purification , Glycosides/pharmacology , Kidney Neoplasms/chemically induced , Kidney Neoplasms/prevention & control , Male , NF-kappa B/antagonists & inhibitors , Plant Extracts/isolation & purification , Plant Extracts/pharmacology , Plant Extracts/therapeutic use , Rats , Rats, Wistar , Signal Transduction/drug effects , Signal Transduction/physiology
13.
J Neurooncol ; 131(3): 459-467, 2017 02.
Article in English | MEDLINE | ID: mdl-27838807

ABSTRACT

Inhibitory activity of a decoction of meadowsweet, given postnatally, was studied in rats at risk for neurogenic and renal tumors initiated by transplacental exposure to ethylnitrosourea (ENU). Chemical analysis of ethanol and aqueous extracts of meadowsweet has shown high content of biologically active flavonoids and tannins. Pregnant rats of LIO strain were given a single i.v. injection of ENU, 75 mg/kg, оn the 21st day of gestation. After weaning at 3 weeks after birth, the offspring were divided into two groups: the first was a positive control (ENU), while rats in the second group (ENU + meadowsweet) were given daily a decoction of meadowsweet as drinking water throughout their lifetime. All rats of the first group (ENU) developed multiple malignant tumors, which occurred in brain (86%), spinal cord (43%), peripheral and cranial nerves (29%) and in kidney (31%). More than one-third of CNS tumors were oligodendrogliomas. Mixed gliomas (oligoastrocytomas) occurred less frequently. All other types including astrocytomas, glioblastomas, and ependymomas were rare. All PNS tumors were neurinomas (schwannomas). The spectrum of tumors was similar in rats of the second group. Postnatal consumption of meadowsweet significantly reduced number of tumor-bearing rats (by 1.2 times), the incidence and multiplicity of CNS tumors (brain-by 2.0 and 2.1 times, respectively; spinal cord-by 3.1 and 3.0 times, respectively) and significantly increased latency period, compared to rats of the first group. No significant reduction in PNS or renal tumors was seen in rats given meadowsweet. Meadowsweet extract can be considered an effective cancer preventive agent especially as a neurocarcinogenesis inhibitor.


Subject(s)
Central Nervous System Neoplasms/drug therapy , Ethylnitrosourea/toxicity , Filipendula , Plant Extracts/administration & dosage , Animals , Central Nervous System Neoplasms/chemically induced , Central Nervous System Neoplasms/pathology , Disease Models, Animal , Female , Kidney Neoplasms/chemically induced , Kidney Neoplasms/drug therapy , Kidney Neoplasms/pathology , Male , Maternal-Fetal Exchange , Plant Extracts/therapeutic use , Pregnancy , Prenatal Exposure Delayed Effects
14.
Inflammopharmacology ; 24(5): 233-251, 2016 Oct.
Article in English | MEDLINE | ID: mdl-27628241

ABSTRACT

Melastoma malabathricum Linn (MM) has high valued for its commercial significance. Indian market (northeast) has great demand for the plants, which extended, its use as a traditional home remedy due to its anti-inflammatory effects. In this study, we scrutinize the therapeutic and protective effect of MM against diethylnitrosamine (DEN) and ferric nitrilotriacetate (Fe-NTA)-induced renal carcinogenesis, renal hyperproliferation, and oxidative stress in rats. Liquid chromatography mass spectroscopy (LC-MS) was used for identification of phytoconstituents. Administration of DEN confirmed the initiation the renal carcinogenesis via enhancing the expansion of tumor incidence. Intraperitoneally, administration of Fe-NTA boost the antioxidant enzymes (phase I), viz., superoxide dismutase (SOD), catalase (CAT), glutathione reductase (GR), glutathione peroxidase (GPx) and phase II, viz., quinone reductase (QR) and glutathione-S-transferase (GST). It also increased the content of renal lipid peroxidation (LPO), hydrogen peroxidase (H2O2) with decrease content in glutathione content (GSH). It also increased the renal biochemical and non-biochemical parameter. It also confirmed the augment the level of thymidine [3H] incorporation into renal DNA, ornithine decarboxylase (ODC) activity and increased the generation of proinflammatory (TNF-α, IL-6 and IL-ß) and inflammatory mediator (PGE2). We also analyzed the macroscopic and histologic of renal tissue. In addition, the effect of phytoconstituent of MM extract was evaluated in silico and free radical scavenging activity against the DPPH and ABTS free radicals. LC-MS confirmed the presence of quercetin >gallic acid in MM extract. Renal carcinogenesis rats treated with MM (100, 250, and 500 mg/kg) confirmed the significantly (P < 0.001) protective effect via reduction the antioxidant (phase I and phase II) enzymes, biochemical parameter and restore the proinflammatory and inflammatory mediator at dose dependent manner. MM altered the ODC and thymidine activity in renal DNA. The chemoprotective effect of MM was confirmed via decreased the renal tumor incidence, which was confirmed by the macroscopic and histopathological observation. Consequently, our result suggests that MM is a potent chemoprotective agent and suppresses DEN+ Fe-NTA-induced renal carcinogenesis, inflammatory reaction, and oxidative stress injury in Wister rats.


Subject(s)
Biomarkers, Tumor/metabolism , Kidney Neoplasms/drug therapy , Kidney Neoplasms/metabolism , Melastomataceae , Oxidative Stress/drug effects , Plant Extracts/therapeutic use , Animals , Antineoplastic Agents, Phytogenic/isolation & purification , Antineoplastic Agents, Phytogenic/pharmacology , Antineoplastic Agents, Phytogenic/therapeutic use , Biomarkers, Tumor/antagonists & inhibitors , Ferric Compounds/toxicity , Inflammation/drug therapy , Inflammation/metabolism , Inflammation Mediators/antagonists & inhibitors , Inflammation Mediators/metabolism , Kidney Neoplasms/chemically induced , Male , Nitrilotriacetic Acid/analogs & derivatives , Nitrilotriacetic Acid/toxicity , Oxidative Stress/physiology , Plant Extracts/isolation & purification , Plant Extracts/pharmacology , Random Allocation , Rats , Rats, Wistar , Treatment Outcome , Tumor Burden/drug effects , Tumor Burden/physiology
15.
Cancer Epidemiol Biomarkers Prev ; 25(12): 1600-1608, 2016 12.
Article in English | MEDLINE | ID: mdl-27555084

ABSTRACT

BACKGROUND: Aristolochia species used in the practice of traditional herbal medicine contains aristolochic acid (AA), an established human carcinogen contributing to urothelial carcinomas of the upper urinary tract. AA binds covalently to genomic DNA, forming aristolactam (AL)-DNA adducts. Here we investigated whether AA is also an etiologic factor in clear cell renal cell carcinoma (ccRCC). METHODS: We conducted a population-based case-control study to investigate the linkage between Aristolochia prescription history, cumulative AA consumption, and ccRCC incidence in Taiwan (5,709 cases and 22,836 matched controls). The presence and level of mutagenic dA-AL-I adducts were determined in the kidney DNA of 51 Taiwanese ccRCC patients. The whole-exome sequences of ccRCC tumors from 10 Taiwanese ccRCC patients with prior exposure to AA were determined. RESULTS: Cumulative ingestion of more than 250 mg of AA increased risk of ccRCC (OR, 1.25), and we detected dA-AL-I adducts in 76% of Taiwanese ccRCC patients. Furthermore, the distinctive AA mutational signature was evident in six of 10 sequenced ccRCC exomes from Taiwanese patients. CONCLUSIONS: This study strongly suggests that AA contributes to the etiology of certain RCCs. IMPACT: The current study offers compelling evidence implicating AA in a significant fraction of the RCC arising in Taiwan and illustrates the power of integrating epidemiologic, molecular, and genetic data in the investigation of cancer etiology. Cancer Epidemiol Biomarkers Prev; 25(12); 1600-8. ©2016 AACR.


Subject(s)
Aristolochic Acids/toxicity , Carcinoma, Renal Cell/chemically induced , DNA Adducts/analysis , Kidney Neoplasms/chemically induced , Kidney/metabolism , Mutation , Adult , Aged , Aged, 80 and over , Aristolochic Acids/analysis , Aristolochic Acids/pharmacology , Carcinogens/toxicity , Carcinoma, Renal Cell/epidemiology , Carcinoma, Renal Cell/genetics , Case-Control Studies , DNA/drug effects , DNA Mutational Analysis , Female , Humans , Kidney Neoplasms/epidemiology , Kidney Neoplasms/genetics , Male , Middle Aged , Mutagens/toxicity , Taiwan/epidemiology
16.
J Occup Environ Med ; 57(1): 68-72, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25563542

ABSTRACT

OBJECTIVE: The purpose of this study was to assess whether occupational exposure to hydrocarbons in the oil-refining activity increases the risk of kidney cancer. METHODS: This case-referent study was nested within the cohort of employees in the oil refinery industry in Finland in 1967 to 1982 (n = 9454). The final data included 30 cases of kidney cancer and 81 age- and sex-matched referents. RESULTS: There was a threefold increase in the kidney cancer risk for exposure to hydrocarbons in crude oil (odds ratio, 3.1; confidence interval, 1.1 to 8.9; 11 exposed cases). The risk was associated with the highest cumulative exposure category to hydrocarbons in crude oil. CONCLUSIONS: Occupational exposure in oil refining, particularly to crude oil, may increase kidney cancer risk. The study assessed historical exposures; further information needs to be collected for evaluating current exposures.


Subject(s)
Extraction and Processing Industry , Kidney Neoplasms/epidemiology , Occupational Diseases/epidemiology , Occupational Exposure/adverse effects , Petroleum/toxicity , Case-Control Studies , Finland/epidemiology , Humans , Hydrocarbons/toxicity , Kidney Neoplasms/chemically induced , Occupational Diseases/chemically induced , Occupational Exposure/analysis , Risk Assessment
17.
Toxicol Appl Pharmacol ; 280(3): 543-9, 2014 Nov 01.
Article in English | MEDLINE | ID: mdl-25218026

ABSTRACT

Ochratoxin A (OTA) has displayed nephrotoxicity and renal carcinogenicity in mammals, however, no clear mechanisms have been identified detailing the relationship between oxidative stress and these toxicities. This study was performed to clarify the relationship between oxidative stress and the renal carcinogenicity induced by OTA. Rats were treated with 70 or 210 µg/kg b.w. OTA for 4 or 13 weeks. In the rats administrated with OTA for 13 weeks, the kidney was damaged seriously. Cytoplasmic vacuolization was observed in the outer stripe of the outer medulla. Karyomegaly was prominent in the tubular epithelium. Kidney injury molecule-1 (Kim-1) was detected in the outer stripe of the outer medulla in both low- and high-dose groups. OTA increased the mRNA levels of clusterin in rat kidneys. Interestingly, OTA did not significantly alter the oxidative stress level in rat liver and kidney. Yet, some indications related to proliferation and carcinogenicity were observed. A dose-related increase in proliferating cell nuclear antigen (PCNA) was observed at 4 weeks in both liver and kidney, but at 13 weeks, only in the kidney. OTA down-regulated reactive oxygen species (ROS) and up-regulated vimentin and lipocalin 2 in rat kidney at 13 weeks. The p53 gene was decreased in both liver and kidney at 13 weeks. These results suggest that OTA caused apparent kidney damage within 13 weeks but exerted limited effect on oxidative stress parameters. It implies that cell proliferation is the proposed mode of action for OTA-induced renal carcinogenicity.


Subject(s)
Cell Adhesion Molecules/metabolism , Cell Proliferation/drug effects , Clusterin/metabolism , Kidney Neoplasms/chemically induced , Ochratoxins/metabolism , Oxidative Stress/physiology , Animals , Cell Adhesion Molecules/genetics , Clusterin/blood , Comet Assay , Glutathione/analysis , Kidney Neoplasms/metabolism , Male , Malondialdehyde/analysis , Ochratoxins/administration & dosage , Ochratoxins/toxicity , RNA/chemistry , RNA/genetics , Rats, Inbred F344 , Reactive Oxygen Species/analysis , Real-Time Polymerase Chain Reaction , Superoxide Dismutase/analysis
18.
Int J Toxicol ; 33(6): 436-49, 2014.
Article in English | MEDLINE | ID: mdl-25260362

ABSTRACT

Empagliflozin, a selective inhibitor of the renal tubular sodium-glucose cotransporter 2, was developed for treatment of type 2 diabetes mellitus. Nonclinical safety of empagliflozin was studied in a battery of tests to support global market authorization. Safety pharmacology studies indicated no effect of empagliflozin on measures of respiratory or central nervous system function in rats or cardiovascular safety in telemeterized dogs. In CD-1 mouse, Wistar Han rat, or beagle dogs up to 13, 26, or 52 weeks of treatment, respectively, empagliflozin exhibited a toxicity profile consistent with secondary supratherapeutic pharmacology related to glucose loss and included decreased body weight and body fat, increased food consumption, diarrhea, dehydration, decreased serum glucose and increases in other serum parameters reflective of increased protein catabolism, gluconeogenesis, and electrolyte imbalances, and urinary changes such as polyuria and glucosuria. Microscopic changes were consistently observed in kidney and included tubular nephropathy and interstitial nephritis (dog), renal mineralization (rat) and tubular epithelial cell karyomegaly, single cell necrosis, cystic hyperplasia, and hypertrophy (mouse). Empagliflozin was not genotoxic. Empagliflozin was not carcinogenic in female mice or female rats. Renal adenoma and carcinoma were induced in male mice only at exposures 45 times the maximum clinical dose. These tumors were associated with a spectrum of nonneoplastic changes suggestive of a nongenotoxic, cytotoxic, and cellular proliferation-driven mechanism. In male rats, testicular interstitial cell tumors and hemangiomas of the mesenteric lymph node were observed; both tumors are common in rats and are unlikely to be relevant to humans. These studies demonstrate the nonclinical safety of empagliflozin.


Subject(s)
Benzhydryl Compounds/toxicity , Glucosides/toxicity , Hypoglycemic Agents/toxicity , Sodium-Glucose Transporter 2 Inhibitors , Animals , Dogs , Drug Evaluation, Preclinical , Female , Kidney/drug effects , Kidney/pathology , Kidney Neoplasms/chemically induced , Kidney Neoplasms/pathology , Male , Mice , Mutagenicity Tests , Rats, Wistar , Toxicity Tests, Chronic , Toxicity Tests, Subchronic
19.
Acta Cir Bras ; 27(9): 634-8, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22936089

ABSTRACT

PURPOSE: To evaluate the antitumor activity of alcoholic extracts of green tea (Camella sinensis). METHODS: Four groups of six Wistar rats were inoculated intramuscularly with 10(6) Walker tumor cells/mL. During 10 days, the animals received by gavage either 0.9% saline solution (Group I; negative control), solution containing 20 mg/Kg of tamoxifen (Group II; positive control), solution containing 0.07 g/Kg alcoholic extract of C. sinensis (Group III), or solution containing 0.14 g/Kg alcoholic extract of C. sinensis (Group IV). Following euthanasia on the tenth day, the tumor, liver, kidneys and spleen were excised and weighed, and tumor volume and tumor growth inhibition were quantified. RESULTS: The average weight of the animals was greater in Group IV than in Group II (p=0.0107). Tumor weight was smaller in Group IV than in Group I (p=0.0062), but did not differ from Group II. Tumor volume was smaller in Groups II and IV than in Group I (p=0.0131). Tumor growth inhibition was observed in Groups II (44.67% ± 32.47), III (16.83% ± 53.02) and IV (66.4% ± 25.82) (p>0.05). The groups did not differ with regard to the weight of the excised organs. CONCLUSION: Alcoholic extracts of green tea have antitumor activity.


Subject(s)
Camellia sinensis/chemistry , Carcinoma 256, Walker/drug therapy , Catechin/pharmacology , Kidney Neoplasms/drug therapy , Liver Neoplasms/drug therapy , Phytotherapy , Plant Extracts/pharmacology , Splenic Neoplasms/drug therapy , Animals , Carcinoma 256, Walker/chemically induced , Kidney Neoplasms/chemically induced , Liver Neoplasms/chemically induced , Male , Rats , Rats, Wistar , Splenic Neoplasms/chemically induced , Tea/chemistry
20.
Acta cir. bras ; 27(9): 634-638, Sept. 2012. ilus, tab
Article in English | LILACS | ID: lil-646730

ABSTRACT

PURPOSE: To evaluate the antitumor activity of alcoholic extracts of green tea (Camella sinensis). METHODS: Four groups of six Wistar rats were inoculated intramuscularly with 10(6) Walker tumor cells/mL. During 10 days, the animals received by gavage either 0.9% saline solution (Group I; negative control), solution containing 20 mg/Kg of tamoxifen (Group II; positive control), solution containing 0.07 g/Kg alcoholic extract of C. sinensis (Group III), or solution containing 0.14 g/Kg alcoholic extract of C. sinensis (Group IV). Following euthanasia on the tenth day, the tumor, liver, kidneys and spleen were excised and weighed, and tumor volume and tumor growth inhibition were quantified. RESULTS: The average weight of the animals was greater in Group IV than in Group II (p=0.0107). Tumor weight was smaller in Group IV than in Group I (p=0.0062), but did not differ from Group II. Tumor volume was smaller in Groups II and IV than in Group I (p=0.0131). Tumor growth inhibition was observed in Groups II (44.67% ± 32.47), III (16.83% ± 53.02) and IV (66.4% ± 25.82) (p>0.05). The groups did not differ with regard to the weight of the excised organs. CONCLUSION: Alcoholic extracts of green tea have antitumor activity.


OBJETIVO: Avaliar a atividade antitumoral do extrato alcoólico do chá verde (C. sinensis). MÉTODOS: Quatro grupos de seis ratos Wistar foram inoculados com 1x10(6) células/mL do tumor de Walker por via intramuscular. Os grupos foram tratados durante 10 dias, por gavagem, com salina 0,9 % (Grupo I, controle negativo), 20 mg/Kg de tamoxifeno (Grupo II, controle positivo) e extrato alcoólico de C. sinensis nas doses de 0,07 g/Kg (Grupo III) ou 0,14 g/Kg (Grupo IV). O volume e a inibição do crescimento tumoral foram calculados. RESULTADOS: A média dos pesos dos animais foi maior no Grupo IV do que no Grupo II (p=0,0107). O peso tumoral do Grupo IV foi menor do que o Grupo I (p=0,0062), mas não houve diferença quando comparado ao Grupo II. O volume tumoral foi menor nos grupos II e IV quando comparados ao Grupo I (p=0,0131). Inibição tumoral foi observada nos Grupos II = 44,67 ± 32,47, III = 16,83 ± 53,02 e IV = 66,4 ± 25,82 (p>0,05). Não houve diferença no peso dos órgãos entre os grupos. CONCLUSÃO: O extrato alcoólico do chá verde possui ação antitumoral.


Subject(s)
Animals , Male , Rats , Camellia sinensis/chemistry , /drug therapy , Catechin/pharmacology , Kidney Neoplasms/drug therapy , Liver Neoplasms/drug therapy , Phytotherapy , Plant Extracts/pharmacology , Splenic Neoplasms/drug therapy , /chemically induced , Kidney Neoplasms/chemically induced , Liver Neoplasms/chemically induced , Rats, Wistar , Splenic Neoplasms/chemically induced , Tea/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL